未登录

S

Sara Baldelli

university of milan

H指数:27

被引数:1,898

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adverse events during intravenous fosfomycin therapy in a real-life scenario. Risk factors and the potential role of therapeutic drug monitoring

BMC INFECTIOUS DISEASES

IF3

2024-06-282

OAAI

Combining clozapine with cariprazine: Two case reports highlighting potential drug-drug interaction

SCHIZOPHRENIA RESEARCH

IF3.5

2024-04-010

PRE

Pharmacokinetic drug-drug interaction between clozapine and brexpiprazole: A case series

SCHIZOPHRENIA RESEARCH

IF3.5

2023-11-010

PRE

New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians

PHARMACEUTICALS

IF4.8

2023-09-154

OAAI

Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects

CARDIOVASCULAR RESEARCH

IF13.3

2022-07-2821

OAAI

Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients

耐多药肺结核患者利奈唑胺的群体药代动力学及靶点达成分析

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2021-11-0713

OAAI

In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5

BIOMEDICINE & PHARMACOTHERAPY

IF7.5

2021-07-019

OAAI

Differences in tenofovir trough concentrations between branded and generic formulations in people taking PrEP

IF3.1

2021-03-010

PRE

Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2020-05-1427

OAAI

Therapeutic drug monitoring and pharmacogenetics of antipsychotics and antidepressants in real life settings: A 5-year single centre experience

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

IF3.8

2020-05-069

PREAI

Unexpected analytical interference in isavuconazole UV determination in a child in therapy with lumacaftor/ivacaftor for cystic fibrosis

CLINICAL CHEMISTRY AND LABORATORY MEDICINE

IF3.7

2019-05-291

PREAI

Pharmacogenetic variants in bipolar disorder with elevated treatment resistance and intolerance: Towards a personalized pattern of care

BIPOLAR DISORDERS

IF4.5

2019-03-204

OAAI

Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

IF3.8

2018-09-209

PREAI

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

PHARMACOPSYCHIATRY

IF2.2

2017-11-278

OAAI

Development of an HPLC-UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients

JOURNAL OF PHARMACEUTICAL ANALYSIS

IF8.9

2016-12-0137

OAAI

When food can make the difference: The case of elvitegravir-based co-formulation

INTERNATIONAL JOURNAL OF PHARMACEUTICS

IF5.2

2016-10-016

OAAI

Determinants of bone diseases in tenofovir-treated HIV patients

IF3.1

2016-06-190

OAAI

Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2016-01-106

OA

Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots

CLINICAL CHEMISTRY AND LABORATORY MEDICINE

IF3.7

2015-01-0143

PREAI

Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Raltegravir in HIV Patients Receiving the Drug by Swallowing or by Chewing

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2012-12-0135

OAAI